Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens - PubMed
6 hours ago
- #Theranostic nanoplatform
- #Cancer targeting
- #NIR-II imaging
- An integrated theranostic nanoplatform was developed using a NIR-II emitting aggregation-induced emission photosensitizer modified with folic acid and the DOTA ligand, then radiolabeled with 68Ga.
- The resulting nanoparticle ([68Ga]DOTA-FA-BBTD-4C NPs) enables precise tumor targeting via folate receptor alpha, providing clear PET/CT imaging within 0.5 hours and fluorescence guidance for tumor resection up to 12 hours.
- The platform also delivers synergistic phototherapy through localized hyperthermia and reactive oxygen species generation, inducing apoptosis and cell cycle arrest to prevent tumor recurrence in a mouse model.